본문으로 건너뛰기
← 뒤로

CCL5: An emerging key target and progress in the targeted therapy of hepatocellular carcinoma.

1/5 보강
Molecular immunology 📖 저널 OA 3.4% 2022: 0/1 OA 2023: 0/1 OA 2024: 0/2 OA 2025: 0/12 OA 2026: 0/11 OA 2022~2026 2025 Vol.187() p. 1-10
Retraction 확인
출처

Liu X, Liang J, Zhao L, Li W, Wang L, Wang X

📝 환자 설명용 한 줄

Hepatocellular carcinoma (HCC) is a highly prevalent and lethal malignancy, presenting significant challenges in clinical diagnosis and treatment.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Liu X, Liang J, et al. (2025). CCL5: An emerging key target and progress in the targeted therapy of hepatocellular carcinoma.. Molecular immunology, 187, 1-10. https://doi.org/10.1016/j.molimm.2025.08.023
MLA Liu X, et al.. "CCL5: An emerging key target and progress in the targeted therapy of hepatocellular carcinoma.." Molecular immunology, vol. 187, 2025, pp. 1-10.
PMID 40885001 ↗

Abstract

Hepatocellular carcinoma (HCC) is a highly prevalent and lethal malignancy, presenting significant challenges in clinical diagnosis and treatment. The chemokine C-C motif ligand 5 (CCL5) plays a pivotal role in HCC pathogenesis. While traditionally viewed primarily as a mediator of immune cell chemotaxis and migration, recent evidence demonstrates that CCL5 directly influences tumor cells, regulating malignant behaviors such as proliferation and invasion. Furthermore, CCL5 recruits diverse immune cells, including immunosuppressive populations, to the tumor microenvironment (TME), remodeling the TME and exerting context-dependent effects that can either promote immune evasion or enhance anti-tumor immunity. This article reviews advances in understanding the mechanisms of CCL5 in HCC and discusses the translational potential of targeting CCL5 for HCC therapy.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반